Pancreatic Cancer: Symptoms and Prognosis

Pancreatic cancer is among the most clinically challenging malignancies encountered in oncology, defined by its late-stage presentation, aggressive biology, and historically poor survival outcomes. This page covers the defining characteristics of pancreatic cancer, the mechanisms driving its lethality, the symptom patterns that guide clinical recognition, and the prognostic boundaries that inform treatment decisions. Understanding these factors is essential for anyone navigating a diagnosis or seeking context about oncology as a field.

Definition and Scope

Pancreatic cancer arises from the cells of the pancreas, an organ performing both endocrine functions (insulin and glucagon secretion) and exocrine functions (digestive enzyme production). Approximately 93% of pancreatic cancers are pancreatic ductal adenocarcinoma (PDAC), originating from the ductal epithelium of the exocrine pancreas, according to the National Cancer Institute (NCI). The remaining cases include less common subtypes such as acinar cell carcinoma, pancreatic neuroendocrine tumors (pNETs), and solid pseudopapillary neoplasms.

The NCI's Surveillance, Epidemiology, and End Results (SEER) program estimates that pancreatic cancer accounts for approximately 3% of all cancers diagnosed in the United States but approximately 7% of all cancer deaths (NCI SEER Data), a disparity that reflects the disease's disproportionate lethality. The 5-year relative survival rate across all stages is approximately 12%, one of the lowest among solid tumor malignancies (NCI SEER).

The pancreas is situated retroperitoneally, behind the stomach, which contributes to both the absence of early physical findings and the late detection that characterizes most cases. Tumors most commonly arise in the head of the pancreas (approximately 60–70% of cases), with the remainder located in the body or tail.

How It Works

Pancreatic ductal adenocarcinoma develops through the accumulation of somatic mutations, most notably in the KRAS oncogene — present in over 90% of PDAC cases according to the National Comprehensive Cancer Network (NCCN). Additional driver mutations frequently involve TP53, CDKN2A, and SMAD4, which progressively disable tumor suppressor pathways. The development of invasive carcinoma is preceded by precursor lesions including pancreatic intraepithelial neoplasia (PanIN), intraductal papillary mucinous neoplasms (IPMNs), and mucinous cystic neoplasms (MCNs).

A defining biological feature of PDAC is its dense desmoplastic stroma — a fibrous microenvironment surrounding tumor cells that impedes drug delivery, suppresses immune infiltration, and promotes metastatic dissemination. This stromal barrier contributes significantly to chemotherapy resistance. Metastasis occurs preferentially to the liver, peritoneum, and lungs.

The clinical consequence of this biology is a long subclinical phase followed by rapid systemic progression once symptoms emerge. By the time a diagnosis is established, approximately 50–55% of patients present with distant metastatic disease (NCI SEER), at which point surgical resection — the only potentially curative intervention — is no longer feasible.

Obstructive jaundice, caused by tumor compression of the common bile duct, represents one mechanism by which head-of-pancreas tumors become symptomatic earlier than body or tail tumors. Tail lesions may grow to considerable size before causing any symptom, making late detection even more common in that anatomical subset.

Common Scenarios

The symptom profile of pancreatic cancer overlaps extensively with benign gastrointestinal conditions, which delays diagnosis in a significant proportion of patients. Clinically recognized symptom patterns include:

Painless jaundice — Yellowing of the skin and sclera caused by biliary obstruction; more characteristic of head-of-pancreas tumors and one of the earlier detectable signs when present.
Epigastric or mid-back pain — A dull, persistent pain radiating to the back; results from tumor invasion of the celiac nerve plexus and is associated with locally advanced or unresectable disease.
Unexplained weight loss and anorexia — Weight loss exceeding 10% of body weight over six months is a common presenting complaint, often linked to malabsorption and tumor-related cachexia; see the related discussion of unexplained weight loss and fatigue as warning signs.
New-onset diabetes mellitus — A subset of patients develops diabetes within 1–2 years preceding diagnosis, as the tumor disrupts endocrine function; new-onset diabetes in adults over 50 with no family history warrants evaluation.
Steatorrhea — Fatty, malodorous stools reflecting exocrine insufficiency when the main pancreatic duct is obstructed.
Thrombophlebitis (Trousseau's syndrome) — Migratory venous thrombosis that may predate the pancreatic cancer diagnosis by months.
Palpable gallbladder (Courvoisier's sign) — A nontender, enlarged gallbladder palpable on physical examination, classically associated with malignant biliary obstruction.

Symptoms vary by tumor location. Head tumors are more likely to produce jaundice and biliary obstruction. Body and tail tumors more commonly present with pain and weight loss as the dominant features, typically at a more advanced stage.

The regulatory context for oncology shapes how diagnostic pathways and treatment standards are codified and overseen at the federal level, including FDA approval processes for pancreatic cancer therapies.

Decision Boundaries

Prognosis in pancreatic cancer is stratified primarily by resectability status, which divides patients into three clinical categories based on tumor relationship to major vascular structures, as defined by NCCN staging criteria:

Resectable — No arterial contact, venous involvement limited to ≤180° of the superior mesenteric vein or portal vein without contour deformity; approximately 15–20% of patients at diagnosis (NCCN Guidelines, Pancreatic Adenocarcinoma).
Borderline resectable — Tumor contact with major vessels meeting specific anatomical thresholds; candidates for neoadjuvant therapy followed by reassessment.
Locally advanced/unresectable — Arterial encasement or unreconstructable venous involvement, without distant metastasis; systemic therapy is the primary approach.
Metastatic — Distant spread, most commonly to liver or peritoneum; systemic therapy focused on disease control and quality of life.

The 5-year survival rate for localized (resectable) disease is approximately 44%, compared to approximately 3% for distant-stage disease (NCI SEER), illustrating the magnitude of stage-dependent prognostic divergence. Among patients who undergo successful resection, CA 19-9 serum tumor marker normalization post-surgery correlates with improved outcomes in studies reviewed by the American Society of Clinical Oncology (ASCO).

Germline mutations — particularly BRCA1, BRCA2, and PALB2 — are identified in approximately 5–10% of pancreatic cancer patients (NCI) and carry therapeutic implications, including eligibility for PARP inhibitor maintenance therapy. Genetic testing and cancer risk assessment has become a standard component of pancreatic cancer workup under NCCN guidelines.

Performance status, as measured by Eastern Cooperative Oncology Group (ECOG) criteria, serves as a gating factor for treatment intensity. Patients with ECOG 0–1 are candidates for combination regimens such as FOLFIRINOX or gemcitabine plus nab-paclitaxel; those with ECOG 2 typically receive gemcitabine monotherapy; those with ECOG ≥3 are generally directed toward palliative care with symptom-focused management.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)